These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 19342222)

  • 21. HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy.
    Lin KT; Wang YW; Chen CT; Ho CM; Su WH; Jou YS
    Clin Cancer Res; 2012 Sep; 18(17):4691-701. PubMed ID: 22811583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
    Sun B; Moibi JA; Mak A; Xiao Z; Roa W; Moore RB
    J Urol; 2009 Mar; 181(3):1361-71. PubMed ID: 19157446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
    Miyake H; Hara I; Gleave ME
    Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents.
    Garcia-Manero G; Issa JP
    Cancer Invest; 2005; 23(7):635-42. PubMed ID: 16305991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
    Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
    Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
    Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of trans-2,3-dimethoxycinnamoyl azide on enhancing antitumor activity of romidepsin on human bladder cancer.
    Fan J; Stanfield J; Guo Y; Karam JA; Frenkel E; Sun X; Hsieh JT
    Clin Cancer Res; 2008 Feb; 14(4):1200-7. PubMed ID: 18281555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein kinase C-alpha antagonizes apoptosis induction by histone deacetylase inhibitors in multidrug resistant leukaemia cells.
    Castro-Galache MD; Menéndez-Gutiérrez MP; Carrasco Garcia E; Garcia-Morales P; Martinez-Lacaci I; Saceda M; Ferragut JA
    Int J Biochem Cell Biol; 2007; 39(10):1877-85. PubMed ID: 17588800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
    Dalgard CL; Van Quill KR; O'Brien JM
    Clin Cancer Res; 2008 May; 14(10):3113-23. PubMed ID: 18483379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
    Hwang JJ; Kim YS; Kim MJ; Jang S; Lee JH; Choi J; Ro S; Hyun YL; Lee JS; Kim CS
    Anticancer Drugs; 2009 Oct; 20(9):815-21. PubMed ID: 19644355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opposite effects of histone deacetylase inhibitors on glucocorticoid and estrogen signaling in human endometrial Ishikawa cells.
    Rocha W; Sanchez R; Deschênes J; Auger A; Hébert E; White JH; Mader S
    Mol Pharmacol; 2005 Dec; 68(6):1852-62. PubMed ID: 16186250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells.
    Mallory JC; Crudden G; Oliva A; Saunders C; Stromberg A; Craven RJ
    Mol Pharmacol; 2005 Dec; 68(6):1747-56. PubMed ID: 16150928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
    Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S
    Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint.
    Magnaghi-Jaulin L; Eot-Houllier G; Fulcrand G; Jaulin C
    Cancer Res; 2007 Jul; 67(13):6360-7. PubMed ID: 17616695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.
    Fritsche P; Seidler B; Schüler S; Schnieke A; Göttlicher M; Schmid RM; Saur D; Schneider G
    Gut; 2009 Oct; 58(10):1399-409. PubMed ID: 19528037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylase inhibitors: overview and perspectives.
    Dokmanovic M; Clarke C; Marks PA
    Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases.
    Hölsken A; Eyüpoglu IY; Lueders M; Tränkle C; Dieckmann D; Buslei R; Hahnen E; Blümcke I; Siebzehnrübl FA
    Acta Neuropathol; 2006 Aug; 112(2):205-15. PubMed ID: 16773328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phospholipase A2-activating protein (PLAA) enhances cisplatin-induced apoptosis in HeLa cells.
    Zhang F; Suarez G; Sha J; Sierra JC; Peterson JW; Chopra AK
    Cell Signal; 2009 Jul; 21(7):1085-99. PubMed ID: 19258036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clusterin: a potential target for improving response to antiestrogens.
    Toffanin S; Daidone MG; Miodini P; De Cecco L; Gandellini P; Cappelletti V
    Int J Oncol; 2008 Oct; 33(4):791-8. PubMed ID: 18813793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.